No clinical evidence for CD4+ cell depletion caused by rituximab

Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

Cancer research·2025

Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.

Cancer chemotherapy and pharmacology·2024

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.

Cancer research communications·2024

Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

The Lancet. Oncology·2020

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Cancer discovery·2018

Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study.

Blood·2026

Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation.

Blood·2026

International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia.

Blood·2026

Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

Blood·2026

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Blood·2026

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

Blood·2026

Catastrophic systemic reaction and fatal disseminated intravascular coagulation following high-pressure intrapelvic povidone-iodine instillation: A case report and review of possible mechanisms.

Urology case reports·2026

Synchronous Coexistence of JAK2 V617F-Positive Essential Thrombocythemia and IgG Kappa Multiple Myeloma in an Octogenarian Patient: A Case Report.

Case reports in medicine·2026

The Vaccine That Was Never Mentioned: A Comparative Medico-Legal Analysis of the Duty to Inform and Document Preventive Immunization, with Proposed Practice Guidelines.

Vaccines·2026

Extranodal Marginal Zone Lymphoma of the Breast in a Patient with Chronic Hepatitis C Infection: A Case Report.

Journal of community hospital internal medicine perspectives·2026

ALK-negative Anaplastic Large Cell Lymphoma Presenting as Back Pain.

Journal of community hospital internal medicine perspectives·2026

Hypoplastic acute myeloid leukemia with aberrant lymphoid antigen expression and EWSR1::FEV fusion: A rare case report and literature review.

Therapeutic advances in hematology·2026

Related Experiment Videos

No clinical evidence for CD4+ cell depletion caused by rituximab

Related Concept Videos

Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.

Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study.

Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation.

International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia.

Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

Catastrophic systemic reaction and fatal disseminated intravascular coagulation following high-pressure intrapelvic povidone-iodine instillation: A case report and review of possible mechanisms.

Synchronous Coexistence of JAK2 V617F-Positive Essential Thrombocythemia and IgG Kappa Multiple Myeloma in an Octogenarian Patient: A Case Report.

The Vaccine That Was Never Mentioned: A Comparative Medico-Legal Analysis of the Duty to Inform and Document Preventive Immunization, with Proposed Practice Guidelines.

Extranodal Marginal Zone Lymphoma of the Breast in a Patient with Chronic Hepatitis C Infection: A Case Report.

ALK-negative Anaplastic Large Cell Lymphoma Presenting as Back Pain.

Hypoplastic acute myeloid leukemia with aberrant lymphoid antigen expression and EWSR1::FEV fusion: A rare case report and literature review.

Related Experiment Videos

No clinical evidence for CD4+ cell depletion caused by rituximab

Related Concept Videos

Related Articles